Navigation Links
Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival

sis pathway, including paclitaxel. In September 2006, Synta reported positive Phase 2b results for STA-4783 in combination with paclitaxel in a double-blind, randomized, multi-center clinical trial in patients with stage IV metastatic melanoma. In November 2006, Synta received Fast Track designation from the FDA for the development of STA-4783 in metastatic melanoma. Synta plans to initiate a pivotal Phase 3 clinical trial for STA-4783 in metastatic melanoma in mid-2007.

Based on the broad-acting potential of its novel mechanism of action, and the activity seen in laboratory experiments in other cancer types, Synta plans to investigate the use of STA-4783 in additional cancers and in combination with other agents, including initiating one or more Phase 2 studies in other cancer indications later in the year.

About Metastatic Melanoma

Melanoma, the most deadly form of skin cancer, arises from melanocytes, the pigment-producing cells of the skin. According to the American Cancer Society, melanoma accounts for approximately five percent of all skin cancers but causes about 75% of all skin cancer-related deaths. An estimated 60,000 people will be diagnosed and nearly 8,200 people will die from melanoma this year in the U.S. alone. If diagnosed and surgically removed while localized in the outermost skin layer, melanoma is potentially curable; however, for patients with metastatic disease, the prognosis is poor, with limited available treatments and an expected survival of only six to nine months. The incidence of melanoma has increased more rapidly than any other cancer during the past ten years. The FDA has not approved a novel, small molecule drug for the treatment of metastatic melanoma in over 30 years.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical cond
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Synta Pharmaceuticals to Host Conference Call Today
2. Synta Oncology Candidate STA-4783 Clinical Trial Results to Be Presented at the ASCO Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:5/22/2015)... , 22 de mayo de 2015 ... DPRX ), una compañía farmacéutica de fase ... de Locilex® (pexiganan cream 0.8%), y colaboradores ... presentación de póster destacando el diseño innovador ... de la Compañía que evalúan Locilex®, su ...
(Date:5/22/2015)... 2015  Effective staffing of key marketing services ... success. Research and consulting leader ... pharmaceutical and biotech marketing managers with metrics detailing ... are being channeled into marketing operations of global ... utilize this report to benchmark their own resource ...
(Date:5/22/2015)... , May 22, 2015 The Assistance Fund ... This program provides financial assistance for copay to individuals ... to announce the addition of the Melanoma Copay Assistance ... Mark McGreevy , executive director. "With each additional program ... of a world where no one is denied access ...
Breaking Medicine Technology:Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2The Assistance Fund Adds Melanoma Assistance Program 2
(Date:5/24/2015)... York (PRWEB) May 24, 2015 ... lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled its next ... of the multidistrict litigation. According to court documents ... of Illinois, the Conference will be convened on ... Testosterone Replacement Therapy Product Liability Litigation - MDL ...
(Date:5/24/2015)... Scottsdale, Arizona (PRWEB) May 24, 2015 ... hired former Millennial Media strategy executive Jay Krihak ... as Medicx looks to ramp up its expertise ... services of the Pharmaceutical and Health sectors. , ... ad tech executive. Most recently, Krihak led sales ...
(Date:5/23/2015)... 2015 On Saturday, May 23, 2015, over ... for Branches Florida City exactly five years to the day ... 2010. , A large fire tore through the Branches United ... 2010 in the middle of the night as neighbors, staff ... declared arson even though it is suspected that the fire ...
(Date:5/23/2015)... 23, 2015 With the implementation of ... finding it increasingly difficult to provide their employees with ... provide adequate insurance for employees stand to face strict ... an integral part of a business’s success or failure. ... businesses, Online USA Doctors has created a varying level ...
(Date:5/23/2015)... Manufacturers are now required to produce water heaters ... Experts in the field agree that the regulation is aimed ... score is what miles per gallon is to your car. ... the minimum HSPF score has been raised to 8.2, technology ... north of 12. Indeed, the regulation was welcomed by environmentalist, ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Medicx Media Solutions Expands Executive Team 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2
... Will Retire from the Lilly ... Board, ... LLY ) has elected Michael L. Eskew, former,chairman and chief executive officer ... Eskew will stand for election,by the shareholders at the 2008 annual meeting in ...
... Feb. 19 WeissComm Partners,the largest independent ... announced the appointment of Tom Jones as ... Corporation,where he was executive director of communications, ... relations programs for the,company,s growth driver brands. ...
... Nation,s 6th Best Hospital, DENVER, Feb. ... Board: GLOB), an international e-Health, medical,information technology ... has signed an agreement with NewYork-Presbyterian,Hospital (NYP), ... in the,world, to license its SafeTrace Tx(R) ...
... under control, researchers say , , TUESDAY, Feb. 19 (HealthDay ... blood pressure under control, and this may help explain ... pressure. , That,s just one of a series of ... of the journal Hypertension . The issue commemorates ...
... While Cutting Prices for,Existing Drugs, According to a ... Mass., Feb. 19 Decision Resources, Inc., one,of ... on,pharmaceutical and healthcare issues, finds that Japan has ... for 2008 and beyond.,The changes reflect the Japanese ...
... Feb. 19 Arcapita Inc., a leading private,equity investment ... its,affiliates have agreed to sell TLC Health Care Services, ... AMED ), for an enterprise value of,$395 million., ... York, TLC is the,largest privately-held home healthcare provider in ...
Cached Medicine News:Health News:Michael L. Eskew Elected to Lilly Board of Directors 2Health News:WeissComm Partners Names Tom Jones Managing Director to Deepen Global Product Communications Offering 2Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 2Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 3Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 4Health News:Hypertension a Health Challenge for Women 2Health News:Hypertension a Health Challenge for Women 3Health News:Japan Backs Away from Making Real Changes to Its Rx Pharma Pricing Mechanism 2Health News:Arcapita to Sell TLC Health Care Services, Inc. for $395 Million 2
... temporary internal drainage from the ureteropelvic junction ... stricture. The segment with no sideports prevents ... preventing ingrowth of the ureteral wall to ... Intended for one-time use. CAUTION: Periodic evaluation ...
Since first designed by Dr. Roy P. Finney in 1978, ACMI™ Classic Ureteral Stents remain the standard for comfort, performance, and quality....
... retrograde or antegrade ureteral ... stent placement. The RB ... band on the delivery ... fluoroscopic visualization during placement. ...
... Used for interoperative placement to ... conduit construction and continent urinary ... packages. Intended for one-time use. ... stent must not remain indwelling ...
Medicine Products: